{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T15:10:38Z","timestamp":1785510638244,"version":"3.56.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2014,10,7]],"date-time":"2014-10-07T00:00:00Z","timestamp":1412640000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Psychiatry"],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1038\/mp.2014.123","type":"journal-article","created":{"date-parts":[[2014,10,7]],"date-time":"2014-10-07T07:58:58Z","timestamp":1412668738000},"page":"1322-1328","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":108,"title":["APOE and BDNF polymorphisms moderate amyloid \u03b2-related cognitive decline in preclinical Alzheimer\u2019s disease"],"prefix":"10.1038","volume":"20","author":[{"given":"Y Y","family":"Lim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V L","family":"Villemagne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S M","family":"Laws","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R H","family":"Pietrzak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P J","family":"Snyder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Ames","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K A","family":"Ellis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Harrington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Rembach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R N","family":"Martins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C C","family":"Rowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C L","family":"Masters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Maruff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,10,7]]},"reference":[{"key":"BFmp2014123_CR1","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/S1474-4422(13)70044-9","volume":"12","author":"VL Villemagne","year":"2013","unstructured":"Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis KA, Salvado O et al. Amyloid \u03b2 deposition, neurodegeneration and cognitive decline in sporadic Alzheimer\u2019s disease: a prospective cohort study. Lancet Neurol 2013; 12: 357\u2013367.","journal-title":"Lancet Neurol"},{"key":"BFmp2014123_CR2","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1016\/j.neuroimage.2012.07.059","volume":"63","author":"BM Jedynak","year":"2012","unstructured":"Jedynak BM, Lang A, Liu B, Katz E, Zhang Y, Wyman BT et al. A computational neurodegenerative disease progression score: method and results with the Alzheimer\u2019s Disease Neuroimaging Initiative cohort. NeuroImage 2012; 63: 1478\u20131486.","journal-title":"NeuroImage"},{"key":"BFmp2014123_CR3","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/nrneurol.2012.263","volume":"9","author":"CC Liu","year":"2013","unstructured":"Liu CC, Kanekiyo T, Xu H, Bu G . Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol 2013; 9: 106\u2013118.","journal-title":"Nat Rev Neurol"},{"key":"BFmp2014123_CR4","doi-asserted-by":"publisher","first-page":"627","DOI":"10.2217\/fnl.11.44","volume":"6","author":"M Fahnestock","year":"2011","unstructured":"Fahnestock M . Brain-derived neurotrophic factor: the link between amyloid-\u03b2 and memory loss. Future Neurol 2011; 6: 627\u2013639.","journal-title":"Future Neurol"},{"key":"BFmp2014123_CR5","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1074\/jbc.M111.295451","volume":"287","author":"CYD Lee","year":"2012","unstructured":"Lee CYD, Tse W, Smith JD, Landreth GE . Apolipoprotein E promotes \u03b2-amyloid trafficking and degradation by modulating microglial cholesterol levels. J Biol Chem 2012; 287: 2032\u20132044.","journal-title":"J Biol Chem"},{"key":"BFmp2014123_CR6","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1073\/pnas.1220484110","volume":"110","author":"PB Verghese","year":"2013","unstructured":"Verghese PB, Castellano JM, Garai K, Wang Y, Jiang H, Shah A et al. ApoE influences amyloid-\u03b2 (A\u03b2) clearance despite minimal apoE\/A\u03b2 association in physiological conditions. Proc Natl Acad Sci USA 2013; 110: 1807\u20131816.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFmp2014123_CR7","doi-asserted-by":"publisher","first-page":"212ra161","DOI":"10.1126\/scitranslmed.3007000","volume":"5","author":"E Hudry","year":"2013","unstructured":"Hudry E, Dashkoff J, Roe AD, Takeda S, Koffie RM, Hashimoto T et al. Gene transfer of human Apoe isoform results in differential modulation of amyloid deposition and neurotoxicity in mouse brain. Sci Transl Med 2013; 5: 212ra161.","journal-title":"Sci Transl Med"},{"key":"BFmp2014123_CR8","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1001\/jamaneurol.2013.2152","volume":"70","author":"BV Zlokovic","year":"2013","unstructured":"Zlokovic BV . Cerebrovascular effects of apolipoprotein E: implications for Alzheimer disease. JAMA Neurol 2013; 70: 440\u2013444.","journal-title":"JAMA Neurol"},{"key":"BFmp2014123_CR9","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1212\/WNL.0000000000000431","volume":"82","author":"EC Mormino","year":"2014","unstructured":"Mormino EC, Betensky RA, Hedden T, Schultz AP, Ward A, Huijbers W et al. Amyloid and APOE4 interact to influence short-term decline in preclinical Alzheimer\u2019s disease. Neurology 2014; 82: 1760\u20131767.","journal-title":"Neurology"},{"key":"BFmp2014123_CR10","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1056\/NEJMoa0809437","volume":"361","author":"RJ Caselli","year":"2009","unstructured":"Caselli RJ, Dueck AC, Osborne D, Sabbagh MN, Connor DJ, Ahern GL et al. Longitudinal modeling of age-related memory decline and the APOE \u025b4 effect. N Engl J Med 2009; 361: 255\u2013263.","journal-title":"N Engl J Med"},{"key":"BFmp2014123_CR11","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1212\/01.wnl.0000304038.37421.cc","volume":"70","author":"S Cosentino","year":"2008","unstructured":"Cosentino S, Scarmeas N, Helzner E, Glymour MM, Brandt J, Albert M et al. APOE \u025b4 allele predicts faster cognitive decline in mild Alzheimer\u2019s disease. Neurology 2008; 70: 1842\u20131849.","journal-title":"Neurology"},{"key":"BFmp2014123_CR12","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/nrn3379","volume":"14","author":"H Park","year":"2013","unstructured":"Park H, Poo MM . Neurotrophin regulation of neural circuit development and function. Nat Rev Neurosci 2013; 14: 7\u201323.","journal-title":"Nat Rev Neurosci"},{"key":"BFmp2014123_CR13","doi-asserted-by":"publisher","first-page":"2490","DOI":"10.1038\/ncomms3490","volume":"4","author":"A Anastasia","year":"2013","unstructured":"Anastasia A, Deinhardt K, Chao MV, Will NE, Irmady K, Lee FS et al. Val66Met polymorphism of BDNF alters prodomain structure to induce neuronal growth cone retraction. Nat Commun 2013; 4: 2490.","journal-title":"Nat Commun"},{"key":"BFmp2014123_CR14","doi-asserted-by":"publisher","first-page":"2494","DOI":"10.1091\/mbc.e12-12-0858","volume":"24","author":"EM Ramser","year":"2013","unstructured":"Ramser EM, Gan KJ, Decker H, Fan EY, Suzuki MM, Ferreira ST et al. Amyloid-\u03b2 oligomers induce tau-independent disruption of BDNF axonal transport via calcineurin activation in cultured hippocampal neurons. Mol Biol Cell 2013; 24: 2494\u20132505.","journal-title":"Mol Biol Cell"},{"key":"BFmp2014123_CR15","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.jalz.2013.05.292","volume":"9","author":"S Feng","year":"2013","unstructured":"Feng S, Sevigny J, Verma A, Bennett D, Lim YY, Maruff P . Genetic and image biomarkers associated with decline in cognitive measures and brain glucose metabolism in populations of early Alzheimer\u2019s disease. Alzheimer Dement 2013; 9: 178.","journal-title":"Alzheimer Dement"},{"key":"BFmp2014123_CR16","doi-asserted-by":"publisher","first-page":"e86498","DOI":"10.1371\/journal.pone.0086498","volume":"9","author":"YY Lim","year":"2014","unstructured":"Lim YY, Villemagne VL, Laws SM, Ames D, Pietrzak RH, Ellis KA et al. BDNF Val66Met moderates A\u03b2-related memory decline and hippocampal atrophy in prodromal Alzheimer\u2019s disease: A preliminary study. PLoS ONE 2014; 9: e86498.","journal-title":"PLoS ONE"},{"key":"BFmp2014123_CR17","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1016\/j.neurobiolaging.2013.05.006","volume":"34","author":"YY Lim","year":"2013","unstructured":"Lim YY, Villemagne VL, Laws SM, Ames D, Pietrzak RH, Ellis KA et al. BDNF Val66Met, A\u03b2 amyloid and cognitive decline in preclinical Alzheimer\u2019s disease. Neurobiol Aging 2013; 34: 2457\u20132464.","journal-title":"Neurobiol Aging"},{"key":"BFmp2014123_CR18","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1016\/j.neurobiolaging.2010.04.007","volume":"31","author":"CC Rowe","year":"2010","unstructured":"Rowe CC, Ellis KA, Rimajova M, Bourgeat P, Pike KE, Jones G et al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging 2010; 31: 1275\u20131283.","journal-title":"Neurobiol Aging"},{"key":"BFmp2014123_CR19","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1017\/S1041610209009405","volume":"21","author":"KA Ellis","year":"2009","unstructured":"Ellis KA, Bush AI, Darby D, De Fazio D, Foster J, Hudson P et al. The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: Methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer\u2019s disease. Int Psychogeriatr 2009; 21: 672\u2013687.","journal-title":"Int Psychogeriatr"},{"key":"BFmp2014123_CR20","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1002\/ana.22068","volume":"68","author":"R Vandenberghe","year":"2010","unstructured":"Vandenberghe R, Van Laere K, Ivanoiu A, Salmon E, Bastin C, Triau E et al. 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. Ann Neurol 2010; 68: 319\u2013329.","journal-title":"Ann Neurol"},{"key":"BFmp2014123_CR21","first-page":"275","volume":"305","author":"CM Clark","year":"2011","unstructured":"Clark CM, Schneider JA, Bedell BJ, Beach TG, Bilker WB, Mintun MA et al. Use of florbetapir-PET for imaging beta-amyloid pathology. J Am Med Soc 2011; 305: 275\u2013283.","journal-title":"J Am Med Soc"},{"key":"BFmp2014123_CR22","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1002\/ana.24040","volume":"74","author":"CC Rowe","year":"2014","unstructured":"Rowe CC, Bourgeat P, Ellis KA, Brown B, Lim YY, Mulligan R et al. Predicting Alzheimer disease with \u03b2-amyloid imaging: results from the Australian imaging, biomarkers, and lifestyle study of ageing. Ann Neurol 2014; 74: 905\u2013913.","journal-title":"Ann Neurol"},{"key":"BFmp2014123_CR23","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1093\/brain\/awt286","volume":"137","author":"YY Lim","year":"2014","unstructured":"Lim YY, Maruff P, Pietrzak RH, Ames D, Ellis KA, Harrington K et al. Effect of amyloid on memory and non-memory decline from preclinical to clinical Alzheimer\u2019s disease. Brain 2014; 137: 221\u2013231.","journal-title":"Brain"},{"key":"BFmp2014123_CR24","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1017\/S1041610213001087","volume":"25","author":"K Harrington","year":"2013","unstructured":"Harrington K, Lim YY, Ellis KA, Copolov C, Ames D, Darby D et al. The effect of A\u03b2 amyloid and APOE \u025b4 on composite cognitive measures in healthy older adults and MCI. Int Psychogeriatr 2013; 25: 1667\u20131677.","journal-title":"Int Psychogeriatr"},{"key":"BFmp2014123_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1212\/WNL.0b013e3182840bbe","volume":"80","author":"CR Jack","year":"2013","unstructured":"Jack CR, Wiste HJ, Lesnick TG, Weigand SD, Knopman DS, Vemuri P et al. Brain \u03b2-amyloid load approaches a plateau. Neurology 2013; 80: 1\u20137.","journal-title":"Neurology"},{"key":"BFmp2014123_CR26","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1037\/0033-2909.112.1.155","volume":"112","author":"J Cohen","year":"1992","unstructured":"Cohen J . A power primer. Psychol Bull 1992; 112: 155\u2013159.","journal-title":"Psychol Bull"},{"key":"BFmp2014123_CR27","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1111\/j.1365-2796.2004.01388.x","volume":"256","author":"RC Petersen","year":"2004","unstructured":"Petersen RC . Mild cognitive impairment as a diagnostic entity. J Int Med 2004; 256: 183\u2013194.","journal-title":"J Int Med"},{"key":"BFmp2014123_CR28","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1212\/WNL.0b013e31826e9ae6","volume":"79","author":"YY Lim","year":"2012","unstructured":"Lim YY, Ellis KA, Pietrzak RH, Ames D, Darby D, Harrington K et al. Stronger effect of amyloid load than APOE genotype on cognitive decline in healthy older adults. Neurology 2012; 79: 1645\u20131652.","journal-title":"Neurology"},{"key":"BFmp2014123_CR29","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/S1474-4422(13)70194-7","volume":"12","author":"SJ Vos","year":"2013","unstructured":"Vos SJ, Xiong C, Visser PJ, Jasielec MS, Hassenstab J, Grant EA et al. Preclinical Alzheimer\u2019s disease and its outcome: a longitudinal cohort study. Lancet Neurol 2013; 12: 957\u2013965.","journal-title":"Lancet Neurol"},{"key":"BFmp2014123_CR30","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1212\/WNL.0b013e3182661f74","volume":"79","author":"PM Doraiswamy","year":"2012","unstructured":"Doraiswamy PM, Sperling RA, Coleman RE, Johnson KA, Reiman EM, Davis MD et al. Amyloid-\u03b2 assessed by florbetapir F 18 PET and 18-month cognitive decline. Neurology 2012; 79: 1636\u20131644.","journal-title":"Neurology"},{"key":"BFmp2014123_CR31","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.jalz.2013.01.009","volume":"10","author":"CM Stonnington","year":"2014","unstructured":"Stonnington CM, Chen K, Lee W, Locke DE, Dueck AC, Liu X et al. Fibrillar amyloid correlates of preclinical cognitive decline. Alzheimer Dement 2014; 10: e1\u2013e8.","journal-title":"Alzheimer Dement"},{"key":"BFmp2014123_CR32","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1001\/archneurol.2007.29","volume":"65","author":"F Irie","year":"2008","unstructured":"Irie F, Fitzpatrick AL, Lopez OL, Kuller LH, Peila R, Newman AB et al. Enhanced risk for Alzheimer disease in persons with type 2 diabetes and APOE epsilon4: The Cardiovascular Health Study Cognition Study. Arch Neurol 2008; 65: 89\u201393.","journal-title":"Arch Neurol"},{"key":"BFmp2014123_CR33","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1212\/WNL.0b013e3182918ca6","volume":"80","author":"CM Roe","year":"2013","unstructured":"Roe CM, Fagan AM, Grant EA, Hassenstab J, Moulder KL, Maue Dreyfus D et al. Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5 years later. Neurology 2013; 80: 1784\u20131791.","journal-title":"Neurology"},{"key":"BFmp2014123_CR34","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1017\/S1041610213000665","volume":"25","author":"R Buckley","year":"2013","unstructured":"Buckley R, Saling MM, Ames D, Rowe CC, Lautenschlager NT, Macaulay SL et al. Factors affecting subjective memory complaints in the AIBL aging study: biomarkers, memory, affect, and age. Int Psychogeriatr 2013; 25: 1307\u20131315.","journal-title":"Int Psychogeriatr"}],"container-title":["Molecular Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/mp2014123.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/mp2014123","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/mp2014123.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T18:14:53Z","timestamp":1684433693000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/mp2014123"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10,7]]},"references-count":34,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["BFmp2014123"],"URL":"https:\/\/doi.org\/10.1038\/mp.2014.123","relation":{},"ISSN":["1359-4184","1476-5578"],"issn-type":[{"value":"1359-4184","type":"print"},{"value":"1476-5578","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,10,7]]},"assertion":[{"value":"19 May 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2014","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2014","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2014","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"CLM is an advisor to Prana Biotechnology Ltd and a consultant to Eli Lilly. RHP and PJS are scientific consultants to Cogstate Ltd. PM is a full-time employee of Cogstate Ltd. DA has served on scientific advisory boards for Novartis, Eli Lilly, Janssen and Pfizer Inc. RNM is a consultant to Alzhyme. CCR has served on scientific advisory boards for Bayer Pharma, Elan Corporation, GE Healthcare and AstraZeneca, has received speaker honoraria from Bayer Pharma and GE Healthcare and has received research support from Bayer Pharma, GE Healthcare, Piramal Lifesciences and Avid Radiopharmaceuticals. VLV served as a consultant for Bayer Pharma and has received research support from a NEDO grant from Japan. All other authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}